What is the optimal timing of antiviral treatment in pregnant hepatitis B carrier with extremely high viral load?

Clicks: 387
ID: 17615
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 10 articles by views in acta obstetricia et gynecologica scandinavica

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We appreciate the comments from Vyas et al. (1) Although our study demonstrated that prediction of infants' immunoprophylaxis failure (IF) is possible in early pregnancy, whether women with extremely high viral load require earlier antiviral treatment for prevention of IF remains unknown.(2) Two randomized controlled trials showed no cases of IF (0/239) after the use of tenofovir disoproxil fumarate (TDF) in women with baseline HBV DNA >5.3log IU/ml in the third trimester.
Reference Key
cheung2019whatacta Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cheung, Ka Wang;Seto, Mimi Tin Yan;Hung Yu Ng, Ernest;
Journal acta obstetricia et gynecologica scandinavica
Year 2019
DOI
10.1111/aogs.13721
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.